Written By: BrightFocus Editorial Staff
The perils of Alzheimer’s extend far beyond memory loss. This three-part series explores the challenging behaviors seen in patients with the disease, the benefits and risks associated with antipsychotic medications that remedy those behaviors, and other treatment options.
Read the whole series, or just take a look at the sections that interest you:
Read an overview of the challenging behaviors associated with Alzheimer’s disease.
Explore the use of antipsychotics to treat the challenging behavioral symptoms of Alzheimer’s disease.
Explore some of the non-antipsychotic treatment options to help manage the challenging behaviors of Alzheimer’s disease.
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research— the Foundation has awarded nearly $300 million in groundbreaking research funding over the past 51 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
This hour-long webinar helps caregivers and patients understand newly approved therapies that treat Alzheimer's itself, not just the symptoms.
Learn what traumatic brain injury is and how it can increase the risk of developing Alzheimer’s disease.
A doctor answers your most pressing questions about the newest Alzheimer’s treatment.
Watch a free online presentation to learn about the importance of early detection of Alzheimer's disease.
Learn how Alzheimer's diagnostic tests, including blood tests, digital tools, and AI could transform early detection and treatment strategies.
Cognito Therapeutics CEO Brent Vaughan spoke about the pivotal HOPE Study, which uses an investigational medical device consisting of headphones and eyewear to deliver sensory stimulation treatment in the comfort of people’s homes.
